PHOSPHATIDYLINOSITOL DERIVATIVE ENANTIOMERS HAVE THE DIFFERENT POTENTIAL FOR THE ANTITUMOR EFFECT AGAINST MALIGNANT PLEURAL MESOTHELIOMA CELLS
We investigated the antitumor effect of the newly synthesized phosphatidylinositol (PI) derivatives 1,2-O-bis-[8-{2-(2- pentyl-cyclopropylmethyl)-cyclopropyl}-octanoyl]-sn-glycero-3-phosphatidyl-D-1-inositol (diDCP-LA-D-PI) and its enantiomer 1,2-O-bis-[8-{2-(2-pentyl-cyclopropylmethyl)-cyclopropyl}-octanoyl]-sn-glycero-3-phosphatidyl-L-1-inositol (diDCP-LA-L-PI) on human malignant pleural mesothelioma (MPM) cells. diDCP-LA-L-PI strikingly reduced cell viability of NCI-H28, NCI-H2052, NCI-H2452, and MSTO-211H MPM cells, with the potential considerably greater than that for diDCPLA-D-PI. The results show that big difference in the potential for the antitumor effect against MPM cells is found between the enantiomers and that diDCP-LA-L-PI could be developed as an effective drug for MPM therapy